These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 25950726)

  • 1. An Overlooked Cardiac Adverse Effect of Letrozol Therapy: Myocardial Infarction due to Coronary Thrombus Formation.
    Yilmaz S; Avci S; Canpolat U; Başar FN
    Breast J; 2015; 21(4):440-1. PubMed ID: 25950726
    [No Abstract]   [Full Text] [Related]  

  • 2. Myocardial infarction due to coronary thrombus formation in a postmenopausal woman with breast cancer after initiation of letrozol therapy.
    Canpolat U; Sunman H; Kaya EB; Aytemir K; Oto A
    Int J Cardiol; 2012 Sep; 160(1):e1-2. PubMed ID: 22245476
    [No Abstract]   [Full Text] [Related]  

  • 3. ATAC trial update.
    Del Mastro L; Venturini M
    Lancet; 2005 Apr 2-8; 365(9466):1225; author reply 1225-6. PubMed ID: 15811447
    [No Abstract]   [Full Text] [Related]  

  • 4. Letrozole withdrawal response in locally advanced breast cancer.
    Lambertini M; Pronzato P; Giraudi S; Levaggi A; Bighin C; Del Mastro L
    Ann Oncol; 2011 Aug; 22(8):1927-8. PubMed ID: 21562073
    [No Abstract]   [Full Text] [Related]  

  • 5. Breast cancer survivors.
    Boyle F; Forbes J
    Aust Fam Physician; 2008 Oct; 37(10):791. PubMed ID: 19013826
    [No Abstract]   [Full Text] [Related]  

  • 6. Erythema multiforme after radiotherapy with aromatase inhibitor administration in breast-conservation treatment for breast cancer.
    Nakatani K; Matsumoto M; Ue H; Nishioka A; Tanaka Y; Kodama H; Sasaguri S; Ogawa Y
    Breast Cancer; 2008; 15(4):321-3. PubMed ID: 18278432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230).
    Eastell R; Hannon RA; Cuzick J; Dowsett M; Clack G; Adams JE;
    J Bone Miner Res; 2006 Aug; 21(8):1215-23. PubMed ID: 16869719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Postmenopausal women with hormone receptor-positive breast cancer: balancing benefit and toxicity from aromatase inhibitors.
    Ingle JN
    Breast; 2013 Aug; 22 Suppl 2():S180-3. PubMed ID: 24074784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of concurrent anastrozole on acute and late side effects of whole breast radiotherapy.
    Valakh V; Trombetta MG; Werts ED; Labban G; Khalid MK; Kaminsky A; Parda D
    Am J Clin Oncol; 2011 Jun; 34(3):245-8. PubMed ID: 20622644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tamoxifen therapy for patients with breast cancer.
    Litton J; Buzdar A; Mac Gregor MC; Gonzalez-Angulo A; Hortobagyi G
    Lancet; 2013 Jun; 381(9883):2077-8. PubMed ID: 23769223
    [No Abstract]   [Full Text] [Related]  

  • 11. Concurrent or sequential adjuvant letrozole and radiotherapy after conservative surgery for early-stage breast cancer (CO-HO-RT): a phase 2 randomised trial.
    Azria D; Belkacemi Y; Romieu G; Gourgou S; Gutowski M; Zaman K; Moscardo CL; Lemanski C; Coelho M; Rosenstein B; Fenoglietto P; Crompton NE; Ozsahin M
    Lancet Oncol; 2010 Mar; 11(3):258-65. PubMed ID: 20138810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative efficacy study of 5-year letrozole or anastrozole in postmenopausal hormone receptor-positive early breast cancer.
    Sendur MA; Aksoy S; Zengin N; Altundag K
    J BUON; 2013; 18(4):838-44. PubMed ID: 24344006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Another pill for breast cancer prevention.
    Johns Hopkins Med Lett Health After 50; 2014 Mar; 26(1):8. PubMed ID: 24937851
    [No Abstract]   [Full Text] [Related]  

  • 14. Sjögren's syndrome and aromatase inhibitors treatment: is there a link?
    Guidelli GM; Martellucci I; Galeazzi M; Francini G; Fioravanti A
    Clin Exp Rheumatol; 2013; 31(4):653-4. PubMed ID: 23558055
    [No Abstract]   [Full Text] [Related]  

  • 15. Adverse events and bone health during anastrozole therapy in postmenopausal Japanese breast cancer patients.
    Sagara Y; Kosha S; Baba S; Dokiya F; Tamada S; Sagara Y; Matsuyama Y; Ohi Y; Ando M; Rai Y; Sagara Y; Douchi T
    Breast Cancer; 2010 Jul; 17(3):212-7. PubMed ID: 19526308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thrombus vaporization by excimer laser angioplasty.
    Sgueglia GA; Niccoli G; Marino M; Crea F
    Cardiovasc Revasc Med; 2010; 11(1):67-8. PubMed ID: 20129364
    [No Abstract]   [Full Text] [Related]  

  • 17. The breast cancer chemoprevention debate.
    Schmidt C
    J Natl Cancer Inst; 2011 Nov; 103(22):1646-7. PubMed ID: 22025628
    [No Abstract]   [Full Text] [Related]  

  • 18. An overview of letrozole in postmenopausal women with hormone-responsive breast cancer.
    Barnadas A; Estévez LG; Lluch-Hernández A; Rodriguez-Lescure A; Rodriguez-Sanchez C; Sanchez-Rovira P
    Adv Ther; 2011 Dec; 28(12):1045-58. PubMed ID: 22068628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New trials highlight breast cancer therapy and prevention.
    Hampton T
    JAMA; 2014 Feb; 311(5):453-4. PubMed ID: 24496521
    [No Abstract]   [Full Text] [Related]  

  • 20. Letrozole in ovulation induction: time to make decisions.
    Polyzos NP; Mauri D; Tzioras S
    Hum Reprod Update; 2009; 15(2):263-4. PubMed ID: 18987099
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.